Valuation: EnteroMedics Inc

Market Cap 16.28M 13.95M 12.99M 11.97M 22.48M 1.56B 22.86M 154M 60.14M 781M 61.13M 59.8M 2.58B P/E 2026 *
-3.29x
P/E 2027 * -2.54x
Enterprise Value 16.28M 13.95M 12.99M 11.97M 22.48M 1.56B 22.86M 154M 60.14M 781M 61.13M 59.8M 2.58B EV / Sales 2026 *
109x
EV / Sales 2027 * 65.1x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 128K 120K 110K 207K 14.36M 211K 1.42M 554K 7.19M 563K 551K 23.74M 250K 214K 199K 184K 345K 23.94M 351K 2.36M 923K 11.99M 939K 918K 39.57M
Net income -4.89M -4.19M -3.9M -3.6M -6.75M -468M -6.86M -46.14M -18.06M -234M -18.36M -17.96M -774M -7.77M -6.65M -6.2M -5.71M -10.73M -744M -10.91M -73.3M -28.69M -373M -29.17M -28.53M -1.23B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-